中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 8
Aug.  2021
Turn off MathJax
Article Contents

Influence of portal vein thrombosis on the prognosis of patients with liver cirrhosis based on propensity score matching

DOI: 10.3969/j.issn.1001-5256.2021.08.017
  • Received Date: 2020-12-18
  • Accepted Date: 2021-01-19
  • Published Date: 2021-08-20
  •   Objective  To investigate the influence of portal vein thrombosis (PVT) on the short-term prognosis of patients with liver cirrhosis and the risk factors for the prognosis of patients with liver cirrhosis.  Methods  A retrospective analysis was performed for the clinical data of the patients with liver cirrhosis who were hospitalized in our hospital from September 2018 to March 2020, among whom 58 patients with PVT were enrolled as PVT group and 116 patients without PVT were enrolled as non-PVT group, and 44 patients were selected from each group based on propensity score matching (PSM) at a ratio of 1∶ 1 to balance the covariates between groups. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups. The Kaplan-Meier method and the log-rank method were used to analyze survival status and bleeding before and after PSM, and the Cox risk model was used to analyze the risk factors for the prognosis of patients with liver cirrhosis.  Results  Before PSM, the non-PVT group had a significantly higher overall survival rate than the PVT group (P=0.008), while after PSM, there was no significant difference in overall survival rate between the two groups (P=0.076). Before PSM, the non-PVT group had significantly lower incidence rates of upper gastrointestinal bleeding or rebleeding than the PVT group before and after PSM (P < 0.001), and the results after PSM were consistent with those before PSM (P=0.028). The multivariate analysis of the prognosis of the patients with liver cirrhosis before PSM showed that PVT (hazard ratio [HR]=2.944, 95% confidence interval [CI]: 1.364-6.441, P=0.007) and Model for End-Stage Liver Disease (MELD) score ≥15 (HR=3.531, 95% CI: 1.630-7.650, P=0.001) were risk factors for short-term death of the patients with liver cirrhosis, and the multivariate analysis after PSM showed that MELD score ≥15 (HR=3.312, 95% CI: 1.049-10.457, P=0.041) was a risk factor for short-term death of the patients with liver cirrhosis.  Conclusion  Liver cirrhosis with PVT increases the risk of upper gastrointestinal bleeding or rebleeding, but it is not an independent risk factor for short-term death in patients with liver cirrhosis. MELD score ≥15 is an independent risk factor for short-term death in patients with liver cirrhosis.

     

  • loading
  • [1]
    QI X. Portal vein thrombosis: Recent advance[J]. Adv Exp Med Biol, 2017, 906: 229-239. DOI: 10.1007/5584_2016_118.
    [2]
    ABDEL-RAZIK A, MOUSA N, ELHELALY R, et al. De-novo portal vein thrombosis in liver cirrhosis: Risk factors and correlation with the Model for End-stage Liver Disease scoring system[J]. Eur J Gastroenterol Hepatol, 2015, 27(5): 585-592. DOI: 10.1097/MEG.0000000000000325.
    [3]
    NORONHA FERREIRA C, MARINHO RT, CORTEZ-PINTO H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study[J]. Liver Int, 2019, 39(8): 1459-1467. DOI: 10.1111/liv.14121.
    [4]
    CHAWLA Y, DUSEJA A, DHIMAN RK. Review article: The modern management of portal vein thrombosis[J]. Aliment Pharmacol Ther, 2009, 30(9): 881-894. DOI: 10.1111/j.1365-2036.2009.04116.x.
    [5]
    OKUDA K, OHNISHI K, KIMURA K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients[J]. Gastroenterology, 1985, 89(2): 279-286. DOI: 10.1016/0016-5085(85)90327-0.
    [6]
    MARUYAMA H, OKUGAWA H, TAKAHASHI M, et al. De novo portal vein thrombosis in virus-related cirrhosis: Predictive factors and long-term outcomes[J]. Am J Gastroenterol, 2013, 108(4): 568-574. DOI: 10.1038/ajg.2012.452.
    [7]
    ENGLESBE M J, KUBUS J, MUHAMMAD W, et al. Portal vein thrombosis and survival in patients with cirrhosis[J]. Liver Transpl, 2010, 16(1): 83-90. DOI: 10.1002/lt.21941.
    [8]
    STINE JG, SHAH PM, CORNELLA SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis[J]. World J Hepatol, 2015, 7(27): 2774-2780. DOI: 10.4254/wjh.v7.i27.2774.
    [9]
    GAO B, XIAO J, ZHANG M, et al. High-density lipoprotein cholesterol for the prediction of mortality in cirrhosis with portal vein thrombosis: A retrospective study[J]. Lipids Health Dis, 2019, 18(1): 79. DOI: 10.1186/s12944-019-1005-8.
    [10]
    LV Y, QI X, HE C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: A randomised controlled trial[J]. Gut, 2018, 67(12): 2156-2168. DOI: 10.1136/gutjnl-2017-314634.
    [11]
    ENDO K, OIKAWA T, KAKISAKA K, et al. The impact of portal vein thrombosis on the prognosis and liver function of nonmalignant cirrhotic patients[J]. Scand J Gastroenterol, 2018, 53(10-11): 1340-1346. DOI: 10.1080/00365521.2018.1503327.
    [12]
    NERY F, CHEVRET S, CONDAT B, et al. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: Results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667. DOI: 10.1002/hep.27546.
    [13]
    BERRY K, TAYLOR J, LIOU IW, et al. Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2015, 13(3): 585-593. DOI: 10.1016/j.cgh.2014.10.010.
    [14]
    LUCA A, CARUSO S, MILAZZO M, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis[J]. Radiology, 2012, 265(1): 124-132. DOI: 10.1148/radiol.12112236.
    [15]
    D'AMICO G, DE FRANCHIS R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators[J]. Hepatology, 2003, 38(3): 599-612. DOI: 10.1053/jhep.2003.50385.
    [16]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [17]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670 -2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
    [18]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 939-946. DOI: 10.3969/j.issn.1001-5256.2018.05.006.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 939-946. DOI: 10.3969/j.issn.1001-5256.2018.05.006.
    [19]
    TANG W, WANG Y, ZHAO XY, et al. Impact of portal vein thrombosis on prognosis of patients with liver cirrhosis[J]. J Clin Hepatol, 2017, 33(3): 466-471. DOI: 10.3969/j.issn.1001-5256.2017.03.014.

    汤雯, 王宇, 赵新颜, 等. 门静脉血栓对肝硬化患者预后的影响[J]. 临床肝胆病杂志, 2017, 33(3): 466-471. DOI: 10.3969/j.issn.1001-5256.2017.03.014.
    [20]
    QI X, DAI J, YANG M, et al. Association between portal vein thrombosis and survival in non-liver-transplant patients with liver cirrhosis: A systematic review of the literature[J]. Gastroenterol Res Pract, 2015, 2015: 480842. DOI: 10.1155/2015/480842.
    [21]
    AMITRANO L, GUARDASCIONE MA, MANGUSO F, et al. The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: Refining short-term prognosis and risk factors[J]. Am J Gastroenterol, 2012, 107(12): 1872-1878. DOI: 10.1038/ajg.2012.313.
    [22]
    CHEN PH, CHEN WC, HOU MC, et al. Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: A cohort study[J]. J Hepatol, 2012, 57(6): 1207-1213. DOI: 10.1016/j.jhep.2012.07.038.
    [23]
    FERREIRA CN, RODRIGUES T, ALEXANDRINO P, et al. Portal vein thrombosis in cirrhotic patients is associated with advanced liver disease and predicts poor long-term prognosis[J]. Hepatology, 2010, 52: 1072a. DOI: 10.1002/hep.23995.
    [24]
    GIRLEANU I, STANCIU C, COJOCARIU C, et al. Natural course of nonmalignant partial portal vein thrombosis in cirrhotic patients[J]. Saudi J Gastroenterol, 2014, 20(5): 288-292. DOI: 10.4103/1319-3767.141687.
    [25]
    SENZOLO M, RIVA N, DENTALI F, et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis[J]. Clin Transl Gastroenterol, 2018, 9(8): 176. DOI: 10.1038/s41424-018-0043-2.
    [26]
    Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. J Clin Hepatol, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.

    中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.202.12.007.
    [27]
    FRANCOZ C, BELGHITI J, VILGRAIN V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: Usefulness of screening and anticoagulation[J]. Gut, 2005, 54(5): 691-697. DOI: 10.1136/gut.2004.042796.
    [28]
    SCHMASSMANN A, ZUBER M, LIVERS M, et al. Recurrent bleeding after variceal hemorrhage: Predictive value of portal venous duplex sonography[J]. AJR Am J Roentgenol, 1993, 160(1): 41-47. DOI: 10.2214/ajr.160.1.8416643.
    [29]
    ATTILI AF, LUPO M, GIGLIOTTI F, et al. Portal vein thrombosis is a risk factor for death and complications in liver cirrhosis[J]. Dig Liver Dis, 2012, 44(Suppl 2): s107. DOI: 10.1016/S1590-865828122960291-6.
    [30]
    JOHN BV, KONJETI R, AGGARWAL A, et al. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis[J]. Ann Hepatol, 2013, 12(6): 952-958. DOI: 10.1016/S1665-2681(19)31301-8.
    [31]
    HUNG HH, CHANG CJ, HOU MC, et al. Efficacy of non-selective β-blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: A randomized controlled trial[J]. J Hepatol, 2012, 56(5): 1025-1032. DOI: 10.1016/j.jhep.2011.12.021.
    [32]
    PERARNAU JM, BAJU A, D'ALTEROCHE L, et al. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis[J]. Eur J Gastroenterol Hepatol, 2010, 22(9): 1093-1098. DOI: 10.1097/MEG.0b013e328338d995.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Article Metrics

    Article views (616) PDF downloads(68) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return